Alzheimer’s study gets funding boost
Tuesday, 14 October, 2008
Pfizer Australia has signed up to partner the CSIRO for its Alzheimer’s disease cluster study.
The Australian Imaging, Biomarker and Lifestyle Flagship Study of Ageing (AIBL) is designed to better understand the causes of Alzheimer’s disease and to discover a method for early diagnosis.
The study is a multi-organisational initiative and has so far recruited over 1000 volunteers. They are being investigated by neuro-imaging, clinical and cognitive testing, blood biomarker samples and health and lifestyle data.
The partnership with Pfizer is worth $1.1 million over three years and will see a panel of biomarkers tested against the volunteer group.
The study’s leader, University of Melbourne’s Professor David Aims, said the main aim of the project was the Holy Grail of Alzheimer’s research – a blood test.
$780m Sydney Biomedical Accelerator gains its founding Executive Director
Professor Victoria Cogger has been appointed as founding Executive Director of the Sydney...
Portable point-of-care test detects four common STIs in under an hour
Australian researchers have developed a portable point-of-care test that detects four common...
AusBiotech and Proto Axiom partner on investor-focused life sciences programs
AusBiotech and Proto Axiom have announced a partnership to strengthen national coordination...
